UV LED Phototherapy Systems
Technology
Applications
Research
News
Partnering
Management
Contact
Company Overview
Opthera, Inc. ("Opthera") is a biomedical company that has licensed key patent(s) for the use of ultra-violet light-emitting diodes ("UV LED") in conducting collaborative research agreements. Opthera is seeking license(s) to key patents for use in commercial tanning applications and in commercial phototherapy applications. Opthera, Inc. does not have a license to any patents for a commercial use; therefore, Opthera, Inc. is also seeking the initial capital investment to help secure license(s) to patent(s) for commercial use in the targeted applications.
Opthera is currently seeking first round start-up funding. Opthera is preparing to conduct additional collaborative research projects internationally. Opthera's devices and research are targeting specific UVA1 wavelengths to treat Systemic Lupus Erythematosus ("SLE") and other autoimmune disorders.
Opthera is developing the first major advancement Systemic Lupus Erythematosus therapy in over 50 years. Backed by 30 years of basic science and clinical research, Opthera intends to develop a commercialized version of a Lupus Phototherapy device that incorporates UV LED’s into a system that provides optimized UV light for the treatment of Systemic Lupus Erythematosus.
Opthera, Inc.'s Annual Shareholders Meeting
Opthera, Inc. ('Opthera') Board of Directors passed a resolution to schedule the Opthera, Inc. 2023 Annual Shareholders Meeting on December 28, 2023 at 2:00 PM ET; for which a limited-access conference call is planned and for which each shareholder is required to email a non-international phone number for an out-going conference call. Opthera is attempting to notify shareholders via the contact method used in previous notices.
Note: A majority of Opthera shareholders have indicated that they would not be available to reconvene the adjourned Opthera, Inc. 2021 Annual Shareholders Meeting during the 2021 calendar year. In your reply, you may indicate your availability to achieve a quorum needed to reconvene the adjourned Opthera, Inc. 2021 Annual Shareholders Meeting.
Latest News Release: July 31, 2009, Albany, NY
TanThera, Inc. ("TanThera") is announcing the receipt of U.S. Food & Drug Administration ("FDA") letter dated May 29, 2009 indicating a clearance for the TanThera-T35 UVA1 Light Emitting Diode Tanning Chamber Section 510(k) premarket notification application stating "Indications for Use: Intended to provide ultraviolet light to tan the skin."
The TanThera-T35 is TanThera's flagship LED Tanning bed design, which would be produced in limited quantities for evaluation by qualified customers only. TanThera believes that it has advanced the state-of-the-art in tanning devices by incorporating UVA1 LEDs that are optimized for tanning without producing the UVC, UVB, or UVA2 spectral lines emitted by mercury-vapor tanning lamps commonly used in other tanning devices. UVA1 is closer to blue light, whereas UVA2 is closer to UVB. Since UVA1 is less energetic than UVA2, UVA1 is thought to be less damaging than UVA2, UVB and UVC.
TanThera intends to promote the use of more precise terms to reduce the confusion surrounding ultraviolet light caused by the broad definition of the terms UVC, UVB, and UVA, which have varied in the scientific literature. Within a single range, the effects of different wavelengths can be vastly different, which causes additional confusion. The confusion resulting from the blurring of the specific wavelengths has created on-going debates over health benefits and risks associated with ultraviolet light. TanThera believes that much of the conflicting advice related to ultraviolet light would be resolved if the terms UVC, UVB, and UVA were abandoned in favor of more accurate descriptors.
The term UVC is defined herein as light from 100 nanometer ("nm") to 280 nm. The term UVB is defined herein as light from 280 nm to 320 nm. The term UVA is defined herein as light from 320 nm to 400 nm. UVA is often sub-divided into UVA1 and UVA2. The term UVA1 is defined herein as light with wavelengths from 340 nm to 400 nm. The term UVA2 is defined herein as light with wavelengths from 320 nm to 340 nm.
TanThera is a New York state corporation which has a mission to commercialize UV LED tanning products and services. TanThera is a wholly owned subsidiary of Opthera, Inc., also a New York state corporation, with a mission to commercialize UV LED tanning and phototherapy products and services.
For more information contact:
Peter Fiset, CEO Opthera, Inc.
5 Upper Loudon Road
Loudonville, NY 12211 USA
email: PeterFiset@Opthera.com
###
All rights reserved